Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma
Michèle Cavo(Unknown), Neil Minton, Argiris Symeonidis(University of Patras), Javier de la Rubia(Universitat de València), Paolo de Fabritiis(St. Eugenio Hospital), Igor Wolfgang Blau(Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie), Miguel‐Teodoro Hernández(Hospital Universitario de Canarias), Renato Zambello(University of Padua), Elisabeth Kueenburg(National and Kapodistrian University of Athens), Jennifer M. Bird(University Hospitals Bristol NHS Foundation Trust), Christian Berthou(Centre Hospitalier Régional Universitaire de Brest), Luciano Masini(Casa di Cura Villa Garda), Pamela Bacon(National and Kapodistrian University of Athens), Barbara Rosettani(National and Kapodistrian University of Athens)
Cited by 1
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719